IFNG and myeloid sarcoma: This was in contrast to RTX-treated MS patients, whose responses were almost stationary (median SARS-CoV-2 IFN-γ at M0 2687.8 mIU/mL vs 2629.4 mIU/mL at M3, p = 0.6).